For the treatment of infantile spasms

SAVINGS AND SUPPORT

Young Doctor Examining Baby Young doctor examing baby

VIGAFYDE™ is backed by our Promise of Support™ Program

The Upsher-Smith Promise of Support™ Program reflects our deep commitment to rare disease care—delivering industry-leading support and resources, removing barriers to access, and simplifying prescribing so you can focus on care.

You start the process, we’ll do the rest

Border Image
1

Two Ways to Prescribe

E-prescribe through your EMR system to our specialty pharmacy partner:

PANTHERx Specialty Pharmacy
1120 Stevenson Mill Road, Suite 400
Coraopolis, PA 15108
NCPDP ID: 6008002

or

Download, print, complete, and fax the VIGAFYDE Prescription Form to:

l-877-788-4948

(Monday-Friday 8 AM-8 PM ET)

If you are sending the prescription on a weekend or after hours, fax to

l-877-827-0395
Prescription and Enrollment Form
Border Image
2

The PROMISE OF SUPPORT™ Program Takes It From Here

We confirm Step 1 is complete—that both physician and patient Vigabatrin REMS Program documents have been submitted.

We determine if the patient is:

  • Covered
  • Not covered or uninsured
  • Eligible for the copay assistance program
  • Requires a prior authorization

If the patient requires a prior authorization or letter of medical necessity, we contact their insurance provider. We then fax all necessary forms to your office for you to complete. While this is being done, a VIGAFYDE starter/bridge supply is sent to the patient. Prior authorization and appeal support is available.

Download a sample letter of medical necessity.

Sample Letter of Medical Necessity
3

VIGAFYDE Is Delivered and Treatment Can Begin

Prescription ships to the patient from a specialty pharmacy partner as soon as enrollment and eligibility have been confirmed.

Questions?

Support is available by phone 24/7.


1-866-934-1954
Concerned mother talking to doctor

Support for you

It is important to us that you have resources and partners that can help make getting VIGAFYDE for your patients as easy as possible. When you prescribe VIGAFYDE, Upsher-Smith’s Promise of Support™ Program offers a spectrum of assistance.

Our access experts help guide you through the process. If a Prior Authorization, Medical Exception, and/or appeals processes are required, we will contact their insurance provider. We then fax all necessary forms to your office for you to complete. While this is being done, a VIGAFYDE starter/bridge supply is sent to the patient.

For patients who do not have insurance, or situations in which VIGAFYDE is not covered by their insurance plan, the Promise of Support™ Program will assess options and provide help in accessing appropriate assistance.

Support for caregivers

Caregivers can expect exceptional support including:

Dollar sign icon

$0 copay

for eligible patients*

Hand holding a person icon

Patient Assistance Program (PAP)* for

patients who are uninsured or underinsured

Plus sign shield with dollar sign

Prior authorization and appeal support

to accelerate access and reduce administrative burden

Quick clock icon

Quick Start medication supply

enables patients to start therapy during the insurance approval process

Pills icon

Bridge medication supply provides access to medication while resolving coverage gaps or refill delays

Pharmacy representative icon

24/7 access to a pharmacist

for personalized help, education, and answers every step of the way

Pharmacy icon

Refill reminders

available

Delivery package icon

Free home delivery

of medication

*Restrictions and limitations apply.

Award-winning specialty pharmacy

VIGAFYDE is available through PANTHERx® Rare, an award-winning specialty pharmacy dedicated to rare disease patients and families.

PANTHERx® Rare is a URAC-certified Rare Disease Pharmacy Center of Excellence and has been awarded the MMIT Patient Choice Award.

Our shared goal is to ensure your patients receive the support needed to stay on medication throughout their treatment journey.

urac Award of Excellence icon
urac Pharmacy Award of Excellence icon
CHC Accredited Orphan Drugs icon
Patient Choice Award icon
Patient Choice Award icon
ACHC Gold Seal of Accreditation

INDICATION

INDICATION AND IMPORTANT SAFETY INFORMATION FOR VIGAFYDETM (vigabatrin) ORAL SOLUTION

INDICATION

VIGAFYDE™ (vigabatrin) Oral Solution is indicated for Infantile Spasms (IS) as monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss.

WARNING: PERMANENT VISION LOSS

See full Prescribing Information for complete Boxed Warning.

  • VIGAFYDE™ (vigabatrin) can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, VIGAFYDE may also decrease visual acuity.
  • Risk increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss.
  • Risk of new and worsening vision loss continues as long as VIGAFYDE is used, and possibly after discontinuing.
  • Baseline and periodic vision assessment is recommended for patients. However, this assessment cannot always prevent vision damage.
  • The onset of vision loss is unpredictable and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.
  • Because of the risk of permanent vision loss, VIGAFYDE is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Vigabatrin REMS Program. Further information is available at www.vigabatrinREMS.com or call 1-866-244-8175.
WARNINGS & PRECAUTIONS
  • Permanent Vision Loss. VIGAFYDE can cause permanent vision loss. The risk of vision loss increases with increasing the dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss. Patient response should be periodically assessed. Patients can be affected with bilateral concentric visual field constriction ranging in severity from mild to severe. Severe cases may be characterized by tunnel vision, which can result in disability. VIGAFYDE also can damage the central retina and may decrease visual acuity. Symptoms of vision loss from VIGAFYDE are unlikely to be recognized by patients or caregivers before vision loss is severe. Vision loss of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function.
  • Monitoring of Vision. Monitoring of vision by an ophthalmic professional with expertise in visual field interpretation and the ability to perform dilated indirect ophthalmoscopy of the retina is recommended. Because vision testing in infants is difficult, vision loss may not be detected until it is severe. For patients receiving VIGAFYDE, vision assessment is recommended at baseline, at least every 3 months while on therapy, and about 3 to 6 months after the discontinuation of therapy. Once detected, vision loss due to VIGAFYDE is not reversible. It is expected that even with frequent monitoring, some patients will develop severe vision loss.
  • Magnetic Resonance Imaging (MRI) Abnormalities in Infants. Abnormal MRI signal changes have been reported in some infants with infantile spasms receiving vigabatrin. These changes generally resolved with discontinuation of treatment.
  • Neurotoxicity. Intramyelinic edema (IME) has been reported in postmortem examination of patients being treated for infantile spasms with vigabatrin. IME has been seen in animals at doses within the human therapeutic range.
  • Suicidal Behavior and Ideation. VIGAFYDE is approved for use in patients 1 month to 2 years of age [see Indication]. VIGAFYDE is not approved for use in adolescents or adults. Antiepileptic drugs (AEDs), including vigabatrin, increase the risk of suicidal thoughts and behavior in adolescents and adults. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
  • Withdrawal of AEDS. VIGAFYDE should be withdrawn gradually.
  • Anemia. VIGAFYDE may cause anemia.
  • Somnolence and Fatigue. VIGAFYDE causes somnolence and fatigue.
  • Weight Gain. VIGAFYDE causes weight gain in pediatric patients.
DRUG INTERACTIONS

VIGAFYDE may decrease phenytoin plasma levels; dosage adjustment may be needed.

ADVERSE REACTIONS
  • In patients with Infantile Spasms (incidence >5% and greater than on placebo): Somnolence, bronchitis, ear infection, and acute otitis media.

The most serious adverse reactions are listed above in the WARNINGS AND PRECAUTIONS section.

Refer to the DOSAGE AND ADMINISTRATION section of the full Prescribing Information for recommended dosing guidelines for VIGAFYDE.

VIGAFYDE is a concentrated solution as compared to other vigabatrin products. Verify strength and the dose of the product prior to prescribing, dispensing, and administering. VIGAFYDE does not require additional reconstitution or dilution prior to administration.

This safety information is not comprehensive. Please refer to the full Prescribing Information, including Boxed Warning for vision loss, WARNINGS AND PRECAUTIONS and Medication Guide. You can also visit www.VIGAFYDE.com, www.upsher-smith.com or call 1-888-650-3789.

You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting www.fda.gov/medwatch.